Shattuck Labs (STTK) Free Cash Flow (2019 - 2026)
Shattuck Labs (STTK) posted quarterly Free Cash Flow of -$13.5 million for Q1 2026, down 12.09% year-over-year from -$15.3 million in Q1 2025, and down 58.86% quarter-over-quarter from -$8.5 million in Q4 2025.
Shattuck Labs (STTK) Free Cash Flow (2019 - 2026) Analysis & Trends
Shattuck Labs (STTK) has reported Free Cash Flow for 8 consecutive years, with -$13.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Free Cash Flow fell 12.09% year-over-year to -$13.5 million; the TTM figure through Mar 2026 stood at -$41.4 million (up 26.64% YoY), while the FY2025 annual figure was -$40.0 million, up 34.04% from the prior year.
- Free Cash Flow eased to -$13.5 million in Q1 2026 per STTK's latest filing, from -$8.5 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$8.5 million in Q4 2025 and bottomed at -$38.8 million in Q3 2022.
- Historically, Free Cash Flow has averaged -$17.8 million across 5 years, with a median of -$16.2 million in 2024.
- Annual changes were most pronounced in 2022 — Free Cash Flow plunged 159.89% — and 2023, when it surged 56.83%.
- Shattuck Labs' Free Cash Flow stood at -$24.5 million in 2022, then advanced by 20.78% to -$19.4 million in 2023, then gained by 10.63% to -$17.4 million in 2024, then surged by 51.12% to -$8.5 million in 2025, then tumbled by 58.86% to -$13.5 million in 2026.
- Business Quant data shows STTK's Free Cash Flow at -$13.5 million in Q1 2026, -$8.5 million in Q4 2025, and -$9.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -389.61 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 437.80 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -2.33 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 477.44 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 292.04 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -95.09 Mn |
| 10 | Shattuck Labs | 962.96 Mn | 962.96 Mn | - | -10.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -10.26 Mn |
| Jun 30, 2026 | -10.26 Mn |
| Mar 31, 2026 | -13.49 Mn |
| Mar 31, 2026 | -13.49 Mn |
| Dec 31, 2025 | -8.49 Mn |
| Dec 31, 2025 | -8.49 Mn |
| Sep 30, 2025 | -9.00 Mn |
| Sep 30, 2025 | -9.00 Mn |
| Jun 30, 2025 | -10.43 Mn |
| Jun 30, 2025 | -10.43 Mn |
| Mar 31, 2025 | -12.03 Mn |
| Mar 31, 2025 | -12.03 Mn |
| Dec 31, 2024 | -17.37 Mn |
| Dec 31, 2024 | -17.37 Mn |
| Sep 30, 2024 | -16.11 Mn |
| Sep 30, 2024 | -16.11 Mn |
| Jun 30, 2024 | -10.94 Mn |
| Jun 30, 2024 | -10.94 Mn |
| Mar 31, 2024 | -16.16 Mn |
| Mar 31, 2024 | -16.16 Mn |